D.E. Shaw & Co’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-10,097
| Closed | -$4K | – | 3772 |
|
|
2016
Q3 | $4K | Hold |
10,097
| – | – | ﹤0.01% | 3341 |
|
|
2016
Q2 | $5K | Sell |
10,097
-196,846
| -95% | -$97.5K | ﹤0.01% | 3318 |
|
|
2016
Q1 | $281K | Buy |
206,943
+146,141
| +240% | +$198K | ﹤0.01% | 3048 |
|
|
2015
Q4 | $89K | Buy |
60,802
+31,841
| +110% | +$46.6K | ﹤0.01% | 3678 |
|
|
2015
Q3 | $46K | Sell |
28,961
-14,913
| -34% | -$23.7K | ﹤0.01% | 3670 |
|
|
2015
Q2 | $75K | Sell |
43,874
-9,315
| -18% | -$15.9K | ﹤0.01% | 3669 |
|
|
2015
Q1 | $74K | Sell |
53,189
-58,128
| -52% | -$80.9K | ﹤0.01% | 3543 |
|
|
2014
Q4 | $168K | Buy |
+111,317
| New | +$168K | ﹤0.01% | 3837 |
|
|
2014
Q3 | – | Sell |
-153,048
| Closed | -$468K | – | 4695 |
|
|
2014
Q2 | $468K | Buy |
+153,048
| New | +$468K | ﹤0.01% | 3584 |
|
|
2014
Q1 | – | Sell |
-79,800
| Closed | -$396K | – | 4976 |
|
|
2013
Q4 | $396K | Buy |
+79,800
| New | +$396K | ﹤0.01% | 3879 |
|
D.E. Shaw & Co's RXII Position: Q4 2016 in Review
D.E. Shaw & Co sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 10,097 shares — an estimated $4K sold.
D.E. Shaw & Co first reported a position in RXII in Q4 2013 and held it in 10 quarters. The position peaked at $468K in Q2 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- D.E. Shaw & Co reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- D.E. Shaw & Co sold 10,097 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $4K.
- D.E. Shaw & Co first reported a position in GALENA BIOPHARMA INC COM in Q4 2013 and held it in 10 quarters.
- D.E. Shaw & Co's GALENA BIOPHARMA INC COM position peaked at $468K in Q2 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on D.E. Shaw & Co's 13F filing for Q4 2016, filed 14 Feb 2017.